'
PL
EN
News

BRASTER’s know-how now protected throughout EU

BRASTER S.A., Polish innovative company using liquid crystal contact thermography technology for breast oncology, has registered its patent for the liquid crystal emulsion composition and manufacturing on all EU markets. This means that, irrespective of what patents the Company has registered in any Member State, the unique proprietary technology underlying the TESTER, the device for early breast pathology diagnosing, will be protected throughout EU. BRASTER has already registered its patents in USA, Canada, China and Australia.

"This extension of the patent protection of our core ingredients and the manufacturing methodology onto the whole EU has opened wide the door for the market launch of our TESTER. Thanks to our efforts, today we have our patents protected on the key markets: EU, USA, Canada, China and Australia. Our exclusive right to market the core components of the TESTER on these markets secures not only our intellectual property but also our future profits. What is more, the registration of our patents on successive markets is pending. It is particularly important that our patents with the European Patent Office prevail over patents registered in individual Member States. This means the registration of the patent with EPO automatically extends the protection on local markets of our choice including Poland." – commented Krzysztof Pawelczyk, BRASTER S.A.’s President.

The TESTER, invented by Polish researchers, is the world’s first device using liquid crystal thermographic matrices for diagnosing breast cancer. As acknowledged by the TjermaCRAC Trial completed in 2013, the TESTER is an efficient diagnostic tool complementary to mammography and ultrasonography, which significantly improves the odds for detecting cancer at a very early development stage.

The device consists of three matrices covered with film coated with a mix of liquid crystals that enables thermal imaging. The TESTER is user-friendly and non-invasive, which means painless and completely safe to the patient. It neither emits nor uses any harmful radiation and is biologically neutral to the skin. The TESTER can be an important accessory in screening a broad range of patients for breast cancer, irrespective of age, tissue structure or temperature.

See also

BRASTER S.A. on its way to Warsaw Stock Exchange GPW's main floor

Read More
BRASTER S.A. on its way to Warsaw Stock Exchange GPW's main floor

BRASTER S.A. has registered a new U.S. patent: another step closer to international markets!

Read More
BRASTER S.A. has registered a new U.S. patent: another step closer to international markets!
1 day 5 days 1 month Period from: to: Volume Share price pl

Raty PayU to możliwość zapłacenia za zakupy w ratach (od 3 do nawet 36)

We use cookies to improve the quality of our service. Using our website without changing the cookie settings in your browser means that you agree to have them saved or used. You can find more information in the Privacy and Cookie Policy